Literature DB >> 9920747

Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway.

N Olsson1, A Siegbahn, G Nilsson.   

Abstract

Serum amyloid A (SAA) is an acute-phase protein and its concentration increases in the blood up to 1000 times during an inflammatory response. Mast cells are known to accumulate in various inflammatory processes, some of which are associated with increased levels of acute-phase reactants such as SAA. We report here that SAA can act as a mast cell chemoattractant. Recombinant SAA at concentrations corresponding to those found during the acute phase induced directional migration of human mast cells. No chemokinetic effect was observed. Preincubation of the cells with pertussis toxin inhibited SAA chemotaxis, suggesting that the effect is mediated by G proteins of the Gi class. Furthermore, chemotaxis was diminished after pretreatment with genistein, a tyrosine kinase inhibitor, or bisindolylmaleimide I, a protein kinase C inhibitor. We suggest that SAA may participate in the migration of mast cells to inflamed tissues during an acute-phase response, acting through a pertussis toxin-sensitive signaling pathway. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920747     DOI: 10.1006/bbrc.1998.9911

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Mast cells in rheumatoid arthritis.

Authors:  Nicola Maruotti; Enrico Crivellato; Francesco Paolo Cantatore; Angelo Vacca; Domenico Ribatti
Journal:  Clin Rheumatol       Date:  2006-05-31       Impact factor: 2.980

2.  Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients.

Authors:  N Olsson; A K Ulfgren; G Nilsson
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

3.  Serum Amyloid A Is Present in Human Saccular Intracranial Aneurysm Walls and Associates With Aneurysm Rupture.

Authors:  Nora Huuska; Eliisa Netti; Riikka Tulamo; Satu Lehti; Behnam Rezai Jahromi; Petri T Kovanen; Mika Niemelä
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-26       Impact factor: 3.148

Review 4.  The cytokine-serum amyloid A-chemokine network.

Authors:  Mieke De Buck; Mieke Gouwy; Ji Ming Wang; Jacques Van Snick; Paul Proost; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

5.  Genetically regulated hepatic transcripts and pathways orchestrate haematological, biochemical and body composition traits.

Authors:  Siriluck Ponsuksili; Nares Trakooljul; Frieder Hadlich; Fiete Haack; Eduard Murani; Klaus Wimmers
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

Review 6.  An Inflammation-Centric View of Neurological Disease: Beyond the Neuron.

Authors:  Stephen D Skaper; Laura Facci; Morena Zusso; Pietro Giusti
Journal:  Front Cell Neurosci       Date:  2018-03-21       Impact factor: 5.505

7.  Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1.

Authors:  Sara Abouelasrar Salama; Mirre De Bondt; Mieke De Buck; Nele Berghmans; Paul Proost; Vivian Louise Soares Oliveira; Flavio A Amaral; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Front Immunol       Date:  2020-05-14       Impact factor: 7.561

Review 8.  Mast Cell and Astrocyte Hemichannels and Their Role in Alzheimer's Disease, ALS, and Harmful Stress Conditions.

Authors:  Paloma A Harcha; Polett Garcés; Cristian Arredondo; Germán Fernández; Juan C Sáez; Brigitte van Zundert
Journal:  Int J Mol Sci       Date:  2021-02-15       Impact factor: 5.923

Review 9.  Serum amyloid A, a host-derived DAMP in pregnancy?

Authors:  Yi-Kai Lin; Ping Zhu; Wang-Sheng Wang; Kang Sun
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

10.  S100A12 suppresses pro-inflammatory, but not pro-thrombotic functions of serum amyloid A.

Authors:  Yuen Ming Chung; Jesse Goyette; Nicodemus Tedla; Kenneth Hsu; Carolyn L Geczy
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.